Eli Lilly and Company

(

LLY

) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 1.1%. By the end of trading, Eli Lilly and Company rose 48 cents (1.2%) to $40.62 on average volume. Throughout the day, 5.2 million shares of Eli Lilly and Company exchanged hands as compared to its average daily volume of 6.1 million shares. The stock ranged in a price between $40.04-$40.68 after having opened the day at $40.15 as compared to the previous trading day's close of $40.15. Other companies within the Drugs industry that increased today were:

Amyris

(

AMRS

), up 27.5%,

Marshall Edwards

(

MSHL

), up 19.6%,

Tengion

(

TNGN

), up 13.8%, and

Dendreon

(

DNDN

), up 11.8%.

Eli Lilly and Company discovers, develops, manufactures, and sells pharmaceutical products worldwide. Eli Lilly and Company has a market cap of $46.6 billion and is part of the

health care

sector. The company has a P/E ratio of 10.4, equal to the average drugs industry P/E ratio and below the S&P 500 P/E ratio of 17.7. Shares are down 3.4% year to date as of the close of trading on Monday. Currently there are three analysts that rate Eli Lilly and Company a buy, two analysts rate it a sell, and 12 rate it a hold.

TheStreet Ratings rates Eli Lilly and Company as a

buy

. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, attractive valuation levels, solid stock price performance, expanding profit margins and notable return on equity. We feel these strengths outweigh the fact that the company shows weak operating cash flow.

On the negative front,

Aoxing Pharmaceutical Company

(

TheStreet Recommends

AXN

), down 13.1%,

Cleveland BioLabs

(

CBLI

), down 13%,

Achillion Pharmaceuticals

(

ACHN

), down 9.6%, and

Rosetta Genomics

(

ROSG

), down 9.3%, were all losers within the drugs industry with

Gilead

(

GILD

) being today's drugs industry loser.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF

(

XPH

) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech

(

BIS

).

null